Advertisement

Advertisement
Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone

Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone

Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance

Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance

In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active surveillance.

Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation

People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session together with World Congress of Cardiology. In particular, patients with prostate cancer had the highest burden of atrial fibrillation, followed by those with colon, lung, and breast cancers.

Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer

In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate lesions.

Novel Combination of Cabozantinib Plus Atezolizumab Shows Benefit in Patients With Advanced Prostate Cancer

The combination of the small-molecule tyrosine kinase inhibitor cabozantinib (inhibits VEGF, AXL, MET, and others)...

New Guideline Tackles Rapidly Evolving Imaging Strategies for Advanced Prostate Cancer

Advances in radiology and molecular imaging have the potential to significantly change how clinicians diagnose, stage, and monitor response to therapy in patients with prostate cancer. However, there are limited data comparing these next-generation imaging modalities to each other and to conventional imaging in men with advanced prostate cancer. ASCO recently released a new set of guidelines to provide evidence- and expert-based recommendations for the optimal use of imaging in this patient population.

Advertisement


Advertisement